Accéder au contenu
Merck

Suppression of human colorectal carcinoma cell growth by wild-type p53.

Science (New York, N.Y.) (1990-08-24)
S J Baker, S Markowitz, E R Fearon, J K Willson, B Vogelstein
RÉSUMÉ

Mutations of the p53 gene occur commonly in colorectal carcinomas and the wild-type p53 allele is often concomitantly deleted. These findings suggest that the wild-type gene may act as a suppressor of colorectal carcinoma cell growth. To test this hypothesis, wild-type or mutant human p53 genes were transfected into human colorectal carcinoma cell lines. Cells transfected with the wild-type gene formed colonies five- to tenfold less efficiently than those transfected with a mutant p53 gene. In those colonies that did form after wild-type gene transfection, the p53 sequences were found to be deleted or rearranged, or both, and no exogenous p53 messenger RNA expression was observed. In contrast, transfection with the wild-type gene had no apparent effect on the growth of epithelial cells derived from a benign colorectal tumor that had only wild-type p53 alleles. Immunocytochemical techniques demonstrated that carcinoma cells expressing the wild-type gene did not progress through the cell cycle, as evidenced by their failure to incorporate thymidine into DNA. These studies show that the wild-type gene can specifically suppress the growth of human colorectal carcinoma cells in vitro and that an in vivo-derived mutation resulting in a single conservative amino acid substitution in the p53 gene product abrogates this suppressive ability.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
p53 (1-81), mutant, GST tagged human, recombinant, expressed in E. coli, ≥80% (SDS-PAGE)
Sigma-Aldrich
p53 (1-81), wild type, GST tagged human, recombinant, expressed in E. coli, ≥80% (SDS-PAGE)